⁍ A vaccine that works is seen as a game-changer in the battle against the novel coronavirus.

---

⁍ The vaccine triggers protective antibodies and T-cells in older age groups, the FT said.

---

⁍ Details of the finding are expected to be published shortly in a clinical journal.

---

– AstraZeneca and the University of Oxford are working on a vaccine to fight the deadly strain of coronavirus that has killed more than a million people around the world, the Financial Times reports. The vaccine, called AZD1222 or ChAdOx1 nCoV-19, appears to have produced “robust immune responses” in healthy adults aged 18 to 55, according to early results from a subset of older participants. The vaccine triggers protective antibodies and T-cells in older age groups, the FT reports, citing two people familiar with the finding. Immunogenicity blood tests carried out on a subset of older participants echo data released in July, which showed the vaccine generated ‘robust immune responses’ in a group of healthy adults aged between 18 and 55, the newspaper reports. Details of the finding are expected to be published shortly in a clinical journal, the FT says. AstraZeneca resumed the US trial of the experimental vaccine after approval by US regulators on Friday, the company said. The vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech’s 22UAy.F candidate. AZD1222 or ChAdOx1 nCoV-19, the vaccine was developed by Oxford University scientists and licensed to AstraZeneca in April, which took on the task of scaling trials and production. The British drugmaker has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.